Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

This clinical trial is evaluating a drug called SNX281 given by itself and in combination with pembrolizumab in participants with advanced solid tumors and lymphoma. The main goals of this study are to: * Find the recommended dose of SNX281 that can be given to participants safely alone and in combination with pembrolizumab. * Learn more about the side effects and safety profile of SNX281 alone and in combination with pembrolizumab * Learn more about pharmacological characteristics of SNX281 alone and in combination with pembrolizumab * Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab